论文部分内容阅读
目的观察大骨节Ⅰ号方丸剂治疗大骨节病的临床疗效。方法选择大骨节病患者187例,随机分为3组:治疗组70例、对照组A 67例、对照组B 50例,分别给予口服大骨节Ⅰ号方丸剂、布洛芬缓释胶囊、维生素C片。以上各组均连续服药3个月后观察疗效,并随访观察半年。以国家“大骨节病治疗效果判定标准(Ws/T79-1996)”和国际通用的“视觉疼痛判定标准(VAS)”来观察治疗效果。结果 3个月疗程结束后,治疗组、对照组A的临床疗效分别为91.43%和89.55%,差异无统计学意义(P>0.05),患者症状和体征改善,关节功能改善。对照组B的疗效仅为22%,和治疗组相比,差异有统计学意义,(P<0.05)。停药半年的随访观察中,治疗组、对照组A比较的临床疗效差异不显著(P>0.05);但治疗组、对照组A与对照组B比较,差异有统计学意义(P<0.05);结论大骨节Ⅰ号方丸剂治疗大骨节病的效果显著,未出现不良反应。
Objective To observe the clinical effect of “Dugu Jieji I # 1 Fang” in treating Kashin-Beck disease. Methods 187 patients with Kashin-Beck disease were randomly divided into three groups: treatment group (70 cases), control group (A): 67 cases, control group (B: 50 cases), oral administration of Dazujie I-square pills, ibuprofen sustained release capsules, C film. The above groups were treated for 3 months after treatment efficacy, and follow-up observation of six months. The treatment effect was observed with the national criteria for the determination of Kashin-Beck disease (Ws / T79-1996) and the international standard for visual acuity (VAS). Results After 3 months of treatment, the clinical efficacy of the treatment group and the control group A were 91.43% and 89.55% respectively, with no significant difference (P> 0.05). The symptoms and signs of the patients improved and the joint function improved. The efficacy of the control group B was only 22%, compared with the treatment group, the difference was statistically significant (P <0.05). There was no significant difference in the clinical efficacy between the treatment group and the control group A (P> 0.05), but the differences between the treatment group, control group A and control group B were statistically significant (P <0.05) . Conclusion The treatment of Kashin-Beck disease with DAGJI No.1 pill has significant effect without adverse reactions.